Margarita M Maramis, Jakobus Gerick Pantouw, Isa Multazam Noor, Andi J Tanra, Pornjira Pariwatcharakul, Nopporn Tantirangsee, Kok Yoon Chee, Win Aung Myint, Tin Oo, Ee-Heok Kua, Tran Van Cuong, Shih-ku Lin, Yu-Tao Xiang, Yang Shu-Yu, Lian Yu Chen, Tan Chay Hoon, Naotaka Shinfuku, Norman Sartorius, Takahiro A Kato, Kang Sim
Background: To date, there has not been an evaluation of antipsychotic prescription practices specific to the Association of Southeast Asian Nations (ASEAN) region. This study examined antipsychotic prescription for schizophrenia patients in ASEAN countries based on Research on Asian Psychotropic Prescription (REAP) survey. Methods: This study used data from the fourth REAP antipsychotic survey (REAP-AP4), conducted between March and May 2016 using standardized procedures. In total, 1817 adult schizophrenia patients from six ASEAN countries were analysed. Results: Prescription formulation was significantly associated with illness duration (G (24) = 150.595, p < .001) and prescribing country (G (20) = 571.423, p < .001). Oral antipsychotic monotherapy was the most common prescription across all illness durations, with a decreasing trend from 3–6 months to 10–20 years. Oral antipsychotic monotherapy was also the most commonly used prescription in almost all countries. The frequency of long-acting injection (LAI)-oral combination antipsychotic prescription increased with the patient’s illness duration and is more commonly prescribed in Malaysia, Singapore, and Thailand. Conclusion: LAI-oral combination antipsychotics were prescribed more frequently within patients with longer duration of illness in more developed countries. Antipsychotic monotherapy and oral antipsychotic prescriptions were prevalent across all illness durations and in most ASEAN countries. © The Royal Australian and New Zealand College of Psychiatrists 2025
Department of Psychiatry, Soetomo General Academic Hospital, Surabaya, Indonesia; Department of Psychiatry, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; Widya Mandala Catholic University, Surabaya, Indonesia; Department of Psychiatry, Soeharto Herdjan Psychiatric Hospital, Jakarta, Indonesia; University Hospital, Makassar, Indonesia; Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Songkhla Psychiatric Hospital (SKPH), Songkhla, Thailand; Department of Psychiatry & Mental Health, Tunku Abdul Rahman Institute of Neurosciences, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; Department of Mental Health, University of Medicine and Mental Health Hospital, Yangon, Myanmar; Department of Psychological Medicine, National University Hospital, Kent Ridge, Singapore; Central Psychiatry Hospital, Hanoi, Viet Nam; Psychiatric Center, Taipei City Hospital, Taipei, Taiwan; Unit of Psychiatry, Department of Public Health and Medicinal Administration, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Psychiatric Center, Taipei City Hospital, Taipei, Taiwan; Department of Pharmacology, National University Hospital, Singapore; International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan; Geneva, Switzerland; Department of Psychiatry, Hokkaido University, Sapporo, Japan; Institute of Mental Health, Singapore, Singapore